Skip to Main Content

Author Details

Darragh G McArt
Queen's University Belfast
2009
62
25
PMIDPaper TitleJournal TitlePublished Year
37189838Transcriptional Profiling of a Patient-Matched Cohort of Glioblastoma (IDH-Wildtype) for Therapeutic Target and Repurposing Drug Identification.Biomedicines2023
37875656Translation of tissue-based artificial intelligence into clinical practice: from discovery to adoption.Oncogene2023
36249564Particle swarm optimization artificial intelligence technique for gene signature discovery in transcriptomic cohorts.Comput Struct Biotechnol J2022
35832628A bespoke target selection tool to guide biomarker discovery in tubo-ovarian cancer.Comput Struct Biotechnol J2022
34235886Ultrasound-Powered Implants: A Critical Review of Piezoelectric Material Selection and Applications.Adv Healthc Mater2021
33928242Evolutionary genetic algorithm identifies <i>IL2RB</i> as a potential predictive biomarker for immune-checkpoint therapy in colorectal cancer.NAR Genom Bioinform2021
34819028Novel deep learning-based solution for identification of prognostic subgroups in liver cancer (Hepatocellular carcinoma).BMC Bioinformatics2021
34188784Robustness of differential gene expression analysis of RNA-seq.Comput Struct Biotechnol J2021
34210300Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer.BMC Urol2021
32856020Prostate cancer heterogeneity assessment with multi-regional sampling and alignment-free methods.NAR Genom Bioinform2020
33122623RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer.Cell Death Dis2020
32684627Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia.Br J Cancer2020
30760519ACE: A Workbench Using Evolutionary Genetic Algorithms for Analyzing Association in TCGA.Cancer Res2019
31493898Defining the molecular evolution of extrauterine high grade serous carcinoma.Gynecol Oncol2019
31346333A Novel Role for Cathepsin S as a Potential Biomarker in Triple Negative Breast Cancer.J Oncol2019
31424551NUQA: Estimating Cancer Spatial and Temporal Heterogeneity and Evolution through Alignment-Free Methods.Mol Biol Evol2019
29045551Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy.Ann Oncol2018
30088816Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy.JCO Precis Oncol2018
30324181Impact of Variable RNA-Sequencing Depth on Gene Expression Signatures and Target Compound Robustness: Case Study Examining Brain Tumor (Glioma) Disease Progression.JCO Precis Oncol2018
30651729Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer.J Oncol2018
29729848Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer.EBioMedicine2018
29412457Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies.J Pathol2018
29719622Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma.Oncotarget2018
29568398<i>Bcl-xL</i> as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in <i>BRAF</i>-mutant stage II and III colon cancer.Oncotarget2018
29598829Depletion of DNMT1 in differentiated human cells highlights key classes of sensitive genes and an interplay with polycomb repression.Epigenetics Chromatin2018
29251737Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer.Lab Invest2018
27255914Embracing an integromic approach to tissue biomarker research in cancer: Perspectives and lessons learned.Brief Bioinform2017
29203879QuPath: Open source software for digital pathology image analysis.Sci Rep2017
28621318Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival.Mod Pathol2017
28561046Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification.Nat Commun2017
28904817IHC-based subcellular quantification provides new insights into prognostic relevance of FLIP and procaspase-8 in non-small-cell lung cancer.Cell Death Discov2017
27965461KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies.Oncotarget2017
26173002p16 as a prognostic indicator in ovarian/tubal high-grade serous carcinoma.Histopathology2016
26283684EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer.Clin Cancer Res2016
27677055Building a 'Repository of Science': The importance of integrating biobanks within molecular pathology programmes.Eur J Cancer2016
27793046Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer.Oncotarget2016
27151745Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer.Clin Cancer Res2016
27197062Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy.Cancer Immunol Res2016
27143038QUADrATiC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics.BMC Bioinformatics2016
27402900samExploreR: exploring reproducibility and robustness of RNA-seq results based on SAM files.Bioinformatics2016
27153559Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer.Oncotarget2016
26695702Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program.Cancer2016
26996207Quantification of HER2 heterogeneity in breast cancer-implications for identification of sub-dominant clones for personalised treatment.Sci Rep2016
25258105Analysis of wntless (WLS) expression in gastric, ovarian, and breast cancers reveals a strong association with HER2 overexpression.Mod Pathol2015
26657114Molecular classification of non-invasive breast lesions for personalised therapy and chemoprevention.Oncotarget2015
26317646Automated tumor analysis for molecular profiling in lung cancer.Oncotarget2015
26315110Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility.Oncotarget2015
26149458Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer.J Transl Med2015
25906747The prognostic value of the stem-like group in colorectal cancer using a panel of immunohistochemistry markers.Oncotarget2015
25814194PICan: An integromics framework for dynamic cancer biomarker discovery.Mol Oncol2015
  • 1 - 50 of 62

Recommended Authors

Center for Individualized Medicine, Mayo Clinic
Career Start Year 2011
Number of shared co-authors 1
Memorial Sloan Kettering Cancer Center
Career Start Year 2011
Number of shared co-authors 0
Princess Maxima Center for Pediatric Oncology
Career Start Year 2008
Number of shared co-authors 0
Leibniz Research Centre for Working Environment and Human Factors at TU Dortmund
Career Start Year 2008
Number of shared co-authors 0
Quantitative Biomedical Research Center
Career Start Year 2007
Number of shared co-authors 0
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 2006
Number of shared co-authors 9
University of Washington
Career Start Year 2006
Number of shared co-authors 2
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 3
University of Colorado Anschutz Medical Campus
Career Start Year 2006
Number of shared co-authors 0
Novartis Institutes for BioMedical Research
Career Start Year 2005
Number of shared co-authors 0
Cancer Science Institute of Singapore, National University of Singapore
Career Start Year 2005
Number of shared co-authors 0
Peter MacCallum Cancer Centre
Career Start Year 2005
Number of shared co-authors 1
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2004
Number of shared co-authors 6
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Career Start Year 2004
Number of shared co-authors 4
Washington University
Career Start Year 2003
Number of shared co-authors 2
Johns Hopkins University School of Medicine
Career Start Year 2003
Number of shared co-authors 0
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 1
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 2
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 1
Institute of Pathology, Ludwig-Maximilians-Universitat Munchen
Career Start Year 2002
Number of shared co-authors 1
University Medical Centre Mannheim, University of Heidelberg
Career Start Year 2000
Number of shared co-authors 4
Fondazione IRCCS Istituto Nazionale dei Tumori
Career Start Year 2000
Number of shared co-authors 1
University of Oslo
Career Start Year 1997
Number of shared co-authors 0
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 0
Dana-Farber Cancer Institute & Harvard School of Public Health
Career Start Year 1996
Number of shared co-authors 2
CRUK Cambridge Institute, University of Cambridge
Career Start Year 1995
Number of shared co-authors 3
Center for Cancer Research, National Cancer Institute
Career Start Year 1994
Number of shared co-authors 0
12224University of California san francisco
Career Start Year 1993
Number of shared co-authors 0
Cancer Research UK Cambridge Institute, University of Cambridge
Career Start Year 1992
Number of shared co-authors 5
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 5

Collaborators

Queens University Belfast Belfast
Co-authored papers 13
Peking University Third Hospital
Co-authored papers 5
Tampere University
Co-authored papers 4
Queen's University Belfast
Co-authored papers 4
Cancer Centre Belfast City Hospital, Queen's University Belfast
Co-authored papers 3
University of Manchester and The Christie NHS Foundation Trust
Co-authored papers 2
University of Manchester, Christie Hospital
Co-authored papers 2
The University of Sydney, Westmead Hospital
Co-authored papers 2
Ankang University
Co-authored papers 2
Queen's University Belfast
Co-authored papers 2
University of Toronto
Co-authored papers 2
University of Manchester
Co-authored papers 2
Queen's University Belfast
Co-authored papers 1
University of Oxford, John Radcliffe Hospital
Co-authored papers 1
Princess Margaret Hospital, University of Toronto
Co-authored papers 1
University of Toronto
Co-authored papers 1
University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center
Co-authored papers 1
University of Pennsylvania School of Medicine
Co-authored papers 1
Co-authored papers 1
Mayo Clinic
Co-authored papers 1
University of Leicester
Co-authored papers 1
Institute of Cancer Research
Co-authored papers 1
Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus
Co-authored papers 1
Northwestern University
Co-authored papers 1
The University of Manchester
Co-authored papers 1
Northwestern Feinberg School of Medicine
Co-authored papers 1
Mount Vernon Cancer Centre
Co-authored papers 1
University of California los angeles
Co-authored papers 1
Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS
Co-authored papers 1
GenomeDx Biosciences Inc.
Co-authored papers 1